Cell Source, Inc. and its peers
2 companies side by side: each figure with its date and source, its rank in the group and its percentile in its sector and country.
Companies in the group
Up to 12. Remove or re-base from the table's column heads.
Keep this group
Save it for yourself or, in a team, for everyone in it.
Suggested peers of Cell Source, Inc.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Zivo Bioscience Inc.ZIVO · 🇺🇸 USASame industry: Biotechnology · Similar size: $20 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $20 M (last known, Jul 30, 2023) · revenue $0 M (year to December 2024)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Karyopharm Therapeutics Inc.KPTI · 🇺🇸 USASame industry: Biotechnology · Similar size: $20 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $20 M (Oct 30, 2026) · revenue $146 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Seres Therapeutics, Inc.MCRB · 🇺🇸 USASame industry: Biotechnology · Similar size: $20 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $20 M (Oct 30, 2026) · revenue $1 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Black Hawk Acquisition CorporationBKHA · 🇺🇸 USASame industry: Biotechnology · Similar size: $20 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $20 M (Oct 30, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Aytu BioscienceAYTU · 🇺🇸 USASame industry: Biotechnology · Similar size: $21 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $21 M (Oct 26, 2026) · revenue $58 M (year to June 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Reviva Pharmaceuticals Holdings, Inc.RVPH · 🇺🇸 USASame industry: Biotechnology · Similar size: $21 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $21 M (last known, Mar 8, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Sigyn Therapeutics, Inc.SIGY · 🇺🇸 USASame industry: Biotechnology · Similar size: $19 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $19 M (last known, Jan 7, 2022)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Cocrystal Pharma, Inc.COCP · 🇺🇸 USASame industry: Biotechnology · Similar size: $19 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $19 M (Oct 30, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Senti Biosciences, Inc.SNTI · 🇺🇸 USASame industry: Biotechnology · Similar size: $19 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $19 M (Oct 30, 2026) · revenue $0 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- BeyondSpring Inc.BYSI · 🇺🇸 USASame industry: Biotechnology · Similar size: $22 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $22 M (Oct 30, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Context Therapeutics Inc.CNTX · 🇺🇸 USASame industry: Biotechnology · Similar size: $22 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $22 M (Oct 27, 2026)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- Lipocine Inc.LPCN · 🇺🇸 USASame industry: Biotechnology · Similar size: $18 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $18 M (Oct 13, 2026) · revenue $2 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
Cell Source, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for its exchange yet), so its valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Cell Source, Inc.base CLCS · 🇺🇸 US Percentile in Healthcare Percentile in USA | BeyondSpring Inc. BYSI · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|
| Size | |||
| Market cap (Better neither way: ranked highest first) | $20 Mlast known, Dec 25, 2022 · Market dataLast known value: no current one2nd of 2 | $22 MOct 30, 2026 · Market data1st of 2 | $21 M2 ranked |
| Net income (Higher is better) | $-5 MFY2024 · SEC2nd of 2 | $-1 MFY2025 · SEC1st of 2 | $-3 M2 ranked |
| Valuation | |||
| Free cash flow yield (Higher is better) | ———— | -92.1%price Oct 30, 2026 · Market dataonly one with it9th3rd | -92.1%— |
| Scorecard | |||
| Scorecard (Higher is better) | 0 of 6FY2024 · Scorecard2nd of 2 | 2 of 9FY2025 · Scorecard1st of 2 | 11% passed2 ranked |
| Valuation checks (Higher is better) | —— | 0 of 4FY2025 · Scorecardonly one with it | 0% passed— |
| Growth checks (Higher is better) | 0 of 2FY2024 · Scorecard2nd of 2 | 1 of 1FY2025 · Scorecard1st of 2 | 50% passed2 ranked |
| Profitability checks (Higher is better) | 0 of 2FY2024 · Scorecard1st of 2 | 0 of 2FY2025 · Scorecard1st of 2 | 0% passed2 ranked |
| Financial health checks (Higher is better) | 0 of 1FY2024 · Scorecard2nd of 2 | 1 of 2FY2025 · Scorecard1st of 2 | 25% passed2 ranked |
| Shareholder returns checks (Higher is better) | 0 of 1FY2024 · Scorecardonly one with it | —— | 0% passed— |
| Ownership | |||
| Held by institutions (Better neither way: ranked highest first) | —— | 13.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are inonly one with it | 13.1%— |
| Institutions holding (Better neither way: ranked highest first) | —— | 192026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are inonly one with it | 19— |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | +0.2 pp2026-Q2 against 2026-Q1 · 13Fonly one with it | +0.2 pp— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Cell Source, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; BeyondSpring Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Free cash flow yield#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Free cash flow yield | In its sector | In its country |
|---|---|---|---|
| Cell Source, Inc. | — | — | — |
| BeyondSpring Inc. | -92.1%fiscal 2025 | 9th percentile in Healthcaremedian -6.3%, 675 companies | 3rd percentile in USAmedian 2.5%, 2,914 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
Ranks need two fiscal years with the figure for at least two of these companies.
| Fiscal year | Cell Source, Inc. | BeyondSpring Inc. |
|---|---|---|
| 2022 | — | $1 MSEC |
| 2021 | — | $1 MSEC |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.